Plus Therapeutics, Inc. announced on March 10, 2025, that it received confirmation from Nasdaq on March 7, 2025, regarding its compliance with Nasdaq’s minimum stockholders’ equity requirement. This confirms the company has resolved a previous deficiency.
As a result of regaining compliance, the company's common stock will continue to be listed and traded on The Nasdaq Capital Market. This outcome is crucial for maintaining market visibility and access to capital.
The company had previously been subject to a Mandatory Panel Monitor with respect to the Equity Rule. This successful resolution removes an immediate threat to its listing status.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.